Business Description
Vaccinex Inc
NAICS : 325412
SIC : 2834
ISIN : US9186403013
Description
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.13 | |||||
9-Day RSI | 28.56 | |||||
14-Day RSI | 36.53 | |||||
3-1 Month Momentum % | 31.27 | |||||
6-1 Month Momentum % | -25.55 | |||||
12-1 Month Momentum % | 24.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -2693.18 | |||||
OCF Margin % | -2693.18 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.15 | |||||
EV-to-EBITDA | -0.15 | |||||
EV-to-Revenue | 4.74 | |||||
EV-to-Forward-Revenue | 58.55 | |||||
EV-to-FCF | -0.18 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -715.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:VCNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaccinex Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.601 | ||
| EPS (TTM) ($) | -10.131 | ||
| Beta | 1.9503 | ||
| 3-Year Sharpe Ratio | -0.9 | ||
| 3-Year Sortino Ratio | -1.05 | ||
| Volatility % | 93.35 | ||
| 14-Day RSI | 36.53 | ||
| 14-Day ATR ($) | 0.085386 | ||
| 20-Day SMA ($) | 1.153202 | ||
| 12-1 Month Momentum % | 24.41 | ||
| 52-Week Range ($) | 0.31 - 1.5 | ||
| Shares Outstanding (Mil) | 2.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaccinex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaccinex Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 13 days | ||
| General meeting for 2025 | 2026-08-04 | In 3 days | ||
| Alzheimer\'s Association International Conference (AAIC) | 2026-07-12 | 1.29 (+3.63%) | ||
| Frontiers in Cancer Immunotherapy | 2026-06-22 | 1.11 (-1.77%) | ||
| Annual report for 2025 | 2026-04-29 | 0.91 (+1.11%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-29 | 0.91 (+1.11%) | ||
| Guidance call for 2025 | 2025-12-04 | 0.69 (+87.39%) | ||
| Guidance call for 2025 | 2025-11-05 | 0.51 (+0.00%) | ||
| 3rd Fluid & Imaging Biomarkers in Neuroscience Summit | 2025-10-07 | 0.64 (+0.00%) |
Show
Entries
Vaccinex Inc Frequently Asked Questions
What is Vaccinex Inc(VCNX)'s stock price today?
The current price of VCNX is $0.85. The 52 week high of VCNX is $1.50 and 52 week low is $0.31.
When is next earnings date of Vaccinex Inc(VCNX)?
The next earnings date of Vaccinex Inc(VCNX) is 2026-08-14 Est..
Does Vaccinex Inc(VCNX) pay dividends? If so, how much?
Vaccinex Inc(VCNX) does not pay dividend.
Guru Commentaries on OTCPK:VCNX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vaccinex Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers